33 related articles for article (PubMed ID: 19701750)
1. LLL-3, a STAT3 inhibitor, represses BCR-ABL-positive cell proliferation, activates apoptosis and improves the effects of Imatinib mesylate.
Mencalha AL; Du Rocher B; Salles D; Binato R; Abdelhay E
Cancer Chemother Pharmacol; 2010 May; 65(6):1039-46. PubMed ID: 19701750
[TBL] [Abstract][Full Text] [Related]
2. [Effects of Sinopodophyllum hexundrum on apoptosis in K562 cells].
Zhou FZ; Wang X; Dai AY; Huang ZL; Li H; Huang NS; Feng WL
Nan Fang Yi Ke Da Xue Xue Bao; 2016 Feb; 37(2):226-231. PubMed ID: 28219868
[TBL] [Abstract][Full Text] [Related]
3. Lack of inhibitory effects of the anti-fibrotic drug imatinib on endothelial cell functions in vitro and in vivo.
Venalis P; Maurer B; Akhmetshina A; Busch N; Dees C; Stürzl M; Zwerina J; Jüngel A; Gay S; Schett G; Distler O; Distler JH
J Cell Mol Med; 2009 Oct; 13(10):4185-91. PubMed ID: 18774958
[TBL] [Abstract][Full Text] [Related]
4. Myeloproliferative Neoplasms: Diseases Mediated by Chronic Activation of Signal Transducer and Activator of Transcription (STAT) Proteins.
Liongue C; Ward AC
Cancers (Basel); 2024 Jan; 16(2):. PubMed ID: 38254802
[TBL] [Abstract][Full Text] [Related]
5. Computational workflow for discovering small molecular binders for shallow binding sites by integrating molecular dynamics simulation, pharmacophore modeling, and machine learning: STAT3 as case study.
Jaradat NJ; Hatmal M; Alqudah D; Taha MO
J Comput Aided Mol Des; 2023 Dec; 37(12):659-678. PubMed ID: 37597062
[TBL] [Abstract][Full Text] [Related]
6. The Role of STATs in Ovarian Cancer: Exploring Their Potential for Therapy.
Standing D; Feess E; Kodiyalam S; Kuehn M; Hamel Z; Johnson J; Thomas SM; Anant S
Cancers (Basel); 2023 Apr; 15(9):. PubMed ID: 37173951
[TBL] [Abstract][Full Text] [Related]
7. The Role of Janus Kinase/STAT3 Pathway in Hematologic Malignancies With an Emphasis on Epigenetics.
Zeinalzadeh E; Valerievich Yumashev A; Rahman HS; Marofi F; Shomali N; Kafil HS; Solali S; Sajjadi-Dokht M; Vakili-Samiani S; Jarahian M; Hagh MF
Front Genet; 2021; 12():703883. PubMed ID: 34992627
[TBL] [Abstract][Full Text] [Related]
8. Thymoquinone Induces Downregulation of BCR-ABL/JAK/STAT Pathway and Apoptosis in K562 Leukemia Cells.
Al-Rawashde FA; Wan Taib WR; Ismail I; Johan MF; Al-Wajeeh AS; Al-Jamal HAN
Asian Pac J Cancer Prev; 2021 Dec; 22(12):3959-3965. PubMed ID: 34967577
[TBL] [Abstract][Full Text] [Related]
9. Mesenchymal soluble factors confer imatinib drug resistance in chronic myelogenous leukemia cells.
Regev O; Kidan N; Nicola M; Khamisie H; Ruthardt M; Mahajna J
Arch Med Sci; 2021; 17(1):266-274. PubMed ID: 33488882
[No Abstract] [Full Text] [Related]
10. STAT3, the Challenge for Chemotherapeutic and Radiotherapeutic Efficacy.
Yang PL; Liu LX; Li EM; Xu LY
Cancers (Basel); 2020 Aug; 12(9):. PubMed ID: 32872659
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological Inhibition of Oncogenic STAT3 and STAT5 Signaling in Hematopoietic Cancers.
Brachet-Botineau M; Polomski M; Neubauer HA; Juen L; Hédou D; Viaud-Massuard MC; Prié G; Gouilleux F
Cancers (Basel); 2020 Jan; 12(1):. PubMed ID: 31963765
[TBL] [Abstract][Full Text] [Related]
12. Negative regulators of STAT3 signaling pathway in cancers.
Wu M; Song D; Li H; Yang Y; Ma X; Deng S; Ren C; Shu X
Cancer Manag Res; 2019; 11():4957-4969. PubMed ID: 31213912
[TBL] [Abstract][Full Text] [Related]
13. Overexpression of RPS27a contributes to enhanced chemoresistance of CML cells to imatinib by the transactivated STAT3.
Wang H; Xie B; Kong Y; Tao Y; Yang G; Gao M; Xu H; Zhan F; Shi J; Zhang Y; Wu X
Oncotarget; 2016 Apr; 7(14):18638-50. PubMed ID: 26942564
[TBL] [Abstract][Full Text] [Related]
14. Targeting JAK kinase in solid tumors: emerging opportunities and challenges.
Buchert M; Burns CJ; Ernst M
Oncogene; 2016 Feb; 35(8):939-51. PubMed ID: 25982279
[TBL] [Abstract][Full Text] [Related]
15. LLL12, a novel small inhibitor targeting STAT3 for hepatocellular carcinoma therapy.
Zuo M; Li C; Lin J; Javle M
Oncotarget; 2015 May; 6(13):10940-9. PubMed ID: 25883212
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of STAT3-interacting protein 1 (STATIP1) promotes STAT3 transcriptional up-regulation and imatinib mesylate resistance in the chronic myeloid leukemia.
Mencalha AL; Corrêa S; Salles D; Du Rocher B; Santiago MF; Abdelhay E
BMC Cancer; 2014 Nov; 14():866. PubMed ID: 25417721
[TBL] [Abstract][Full Text] [Related]
17. STAT inhibitors for cancer therapy.
Furqan M; Akinleye A; Mukhi N; Mittal V; Chen Y; Liu D
J Hematol Oncol; 2013 Dec; 6():90. PubMed ID: 24308725
[TBL] [Abstract][Full Text] [Related]
18. Forkhead box M1 (FoxM1) gene is a new STAT3 transcriptional factor target and is essential for proliferation, survival and DNA repair of K562 cell line.
Mencalha AL; Binato R; Ferreira GM; Du Rocher B; Abdelhay E
PLoS One; 2012; 7(10):e48160. PubMed ID: 23110199
[TBL] [Abstract][Full Text] [Related]
19. Role of STAT3 in Transformation and Drug Resistance in CML.
Nair RR; Tolentino JH; Hazlehurst LA
Front Oncol; 2012; 2():30. PubMed ID: 22649784
[TBL] [Abstract][Full Text] [Related]
20. A comparative proteomic study identified LRPPRC and MCM7 as putative actors in imatinib mesylate cross-resistance in Lucena cell line.
Corrêa S; Pizzatti L; Du Rocher B; Mencalha A; Pinto D; Abdelhay E
Proteome Sci; 2012 Mar; 10():23. PubMed ID: 22458888
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
